BTIG analyst Matt VanVliet maintains RingCentral (NYSE:RNG) with a Buy and lowers the price target from $120 to $105.
IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?
IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the second quarter ending on June 30, 2023.
